The Food and Drug Administration (FDA) this week approved Caplyta (lumateperone), an oral atypical a...
Treatment targeting amyloid beta—a protein that has long been assumed to cause Alzheimer’s disease (...
The Food and Drug Administration (FDA) this week approved Caplyta (lumateperone), an oral atypical a...
Treatment targeting amyloid beta—a protein that has long been assumed to cause Alzheimer’s disease (...